在非人类灵长类动物中快速纠正低血糖状态,使用葡萄糖长溶解微针贴片
Xiang Yu1, Xueyu Wen2, Jianchen Xu3
1Affiliated Huzhou Hospital, School of Medicine, Zhejiang University, Huzhou Central Hospital, Huzhou, Zhejiang 313000, China.
ACS biomaterials science & engineering
|April 8, 2024
概括
一种新的含葡萄糖微针 (GLMN) 贴片为严重低血糖症提供了更快,更有效的治疗方法. 这种易于使用的贴片提供快速和持续的血糖控制,改善紧急护理.
科学领域:
- 生物医学工程 生物医学工程
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 严重的低血糖症需要及时给予葡萄糖,但目前的方法复杂且低效.
- 现有的葡萄糖治疗涉及溶解和注射器填充,导致延迟,并需要多次剂量,由于短的血半衰期.
研究的目的:
- 开发和评估含有葡萄糖的长溶性微针 (GLMN) 补丁,用于快速和持续治疗严重低血糖症.
- 为了比较不同尺寸的GLMN贴片的疗效,以改善药物输送和血糖控制.
主要方法:
- 制造三种不同尺寸 (长,中,短) 的含有葡萄糖的微针 (MN) 贴片.
- 评估MN贴片的机械强度,葡萄糖的剂量容量和皮肤插入深度.
- 在大鼠和 rhesus 子模型中评估葡萄糖透性,全身吸收和低血糖逆转.
主要成果:
- 较长的GLMN贴片显示出更高的机械强度和更深的皮肤插入.
- 在动物模型中,GLMN贴片促进了快速的葡萄糖透和全身吸收,在15分钟内逆转低血糖.
- 该GLMN贴片提供了持续的血糖控制,归因于有效的药物透和微针基的药物储存效应.
结论:
- 开发的GLMN贴片提供了一个有希望的,用户友好的策略,用于快速和持续地扭转严重低血糖症.
- 这种微针技术提高了葡萄糖递送效率,解决了传统葡萄糖递送的局限性.
- GLMN贴片代表了严重低血糖症紧急治疗的重大进展,为患者提供了更好的治疗结果.
相关概念视频
Hypoglycemia and Glucagon
257
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
Hormones Regulating Blood Glucose
3.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.3K
Insulin: Dosing Regimen and Adverse Effects
169
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
169
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K


